Drug Trial Radar · NCT00450437
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Last checked: Nov 19, 2026Latest source record: Jan 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,539
Actual
Start
Mar 2007
Primary completion
Aug 2007
Study completion Jan 2008
Sponsor
- Lead sponsor
- Novartis VaccinesNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 11 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
Conditions
- Meningococcal Infections
- Meningococcal Meningitis
Interventions
MenACWY CRMBiological
One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
Meningococcal ACWY Conjugate vaccineBiological
One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 YearsTime frame: 28 days after vaccination
- Percentage of Seroresponders, Ages 11 to 18 YearsTime frame: 28 days after vaccination
- Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 YearsTime frame: 6 days after vaccination
- Percentage of Seroresponders, Ages 19 to 55 YearsTime frame: 28 days after vaccination
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Fremont, California
Site not named
Fresno, California
Site not named
Hayward, California
Site not named
Oakland, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
San Jose, California
Site not named
Denver, Colorado
Site not named
Atlanta, Georgia
Site not named
Marietta, Georgia
Site not named
Woodstock, Georgia
Site not named
Chicago, Illinois
Site not named
Bardstown, Kentucky
Site not named
Annapolis, Maryland
Site not named
Baltimore, Maryland
Site not named
Frederick, Maryland
Site not named
Boston, Massachusetts
Site not named
Fall River, Massachusetts
Site not named
Lebanon, New Hampshire
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Site not named
South Euclid, Ohio
Site not named
Carnegie, Pennsylvania
Site not named
Erie, Pennsylvania
Site not named
Greenville, Pennsylvania
Site not named
Grove City, Pennsylvania
Site not named
Harleyville, Pennsylvania
Site not named
Jefferson Borough, Pennsylvania
Site not named
Latrobe, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Sellersville, Pennsylvania
Site not named
Uniontown, Pennsylvania
Site not named
Upper Saint Clair, Pennsylvania
Site not named
Washington, Pennsylvania
Site not named
Wexford, Pennsylvania
Site not named
Galveston, Texas
Site not named
Salt Lake City, Utah
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.